In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.
The explosion of genuine high throughput technologies has allowed large compound libraries to be screened with ever-increasing biological specificity, exacerbating the problem of lead candidate selection for subsequent drug development. To avoid creating a bottleneck, compounds identified from the high throughput screens undergo lead optimisation by employing medium-throughput screen which permits ranking in terms of their basic absorption, distribution, metabolism, excretion (ADME) and toxicological properties. The historical role of the CRO in the drug discovery/development continuum has been to perform efficacy and toxicology studies, simply to support the regulatory submission of lead candidates. This situation is, however, changing with the development of preclinical lead optimisation technologies facilitating the selection of leading candidates, thereby bridging the gap between high throughput efficacy screens and conventional safety assessment programmes.
Atterwill
C K
CK
Biosciences Division, Huntingdon Life Sciences, Woolley Road, Alconbury, Huntingdon, Cambridgeshire PE28 4HS, UK.
Wing
M G
MG
D017277:Drug Approval; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000633:toxicity; D007880:Legislation, Drug; D009152:Mutagenicity Tests; D013678:Technology, Pharmaceutical
D015507:Drugs, Investigational